Thailand IVF Pre-Treatment Examination: Complete Guide, Checklist, Timeline & Pitfalls

Real consultation scenario opening

The pre-treatment examination for Thailand IVF is essentially a comprehensive assessment before entering the ovarian stimulation cycle. The results directly influence the choice of stimulation protocol, medication dosage adjustments, and cycle success rate. The following is explained from five dimensions: test checklist, timeline, age-specific differences, common misconceptions, and key indicator interpretation.

I. Overview of Pre-Treatment Tests for Thailand IVF

Pre-treatment tests are divided into three categories: female tests, male tests, and tests for both partners. The following are core tests generally required by Thai hospitals. Test reports from reproductive centers in top-tier Chinese hospitals are mostly accepted, but English translations or notarized translations must be provided.

II. Age-Specific Differences in Pre-Treatment Tests

Age is a core variable affecting ovarian response and embryo quality. The focus of pre-treatment tests varies significantly across different age groups.

Under 35 years old

• Basic hormone tests + AMH + AFC are generally sufficient to reflect ovarian status.
• Chromosomal testing can be chosen as needed if there is no history of recurrent miscarriage or family genetic disorders.
• One semen analysis is sufficient; if normal, no repeat is needed.

35–40 years old

• The accuracy of AMH and AFC combined for assessing ovarian reserve declines. Consider adding Vitamin D testing (Vitamin D deficiency occurs in about 60% of people over 35 and is linked to oocyte quality).
• Thyroid autoantibodies (TPOAb, TGAb) should be included, as subclinical thyroid dysfunction is more common in this age group.
• Male sperm DNA fragmentation index testing is valuable, especially if there is a history of miscarriage.

Over 40 years old

• In addition to the above, add assessments related to endometrial receptivity (e.g., hysteroscopy), as the incidence of uterine cavity abnormalities (polyps, adhesions, endometritis) increases in this age group.
• Genetic counseling and feasibility assessment for PGT-A (Preimplantation Genetic Testing for Aneuploidy) should be completed in advance.
• Male testing should not be overlooked: sperm DNA fragmentation index tends to rise significantly in men over 40, affecting embryo developmental potential.

III. Timeline: When to Do Each Test

Scheduling pre-treatment tests for Thailand IVF requires considering the validity of test results, the acceptance period of Thai hospitals, and non-medical factors such as visas and travel plans.

Working backwards: If you plan to travel to Thailand in three months, you should start basic tests like AMH, chromosomal karyotyping, and infectious disease screening immediately. The hormone panel and AFC can be completed on cycle day 2–3 of your last menstrual period before departure, ensuring the reports are still valid when you arrive in Thailand.

IV. Most Easily Overlooked Details

The following four items are most often underestimated or missed during preparation, yet they have a direct impact on cycle decisions in clinical practice.

• Vitamin D Level: Thailand has abundant sunshine, but Vitamin D deficiency is common in Chinese populations. Vitamin D receptors are expressed in the ovaries, endometrium, and immune regulation. Severe deficiency may affect follicular development and endometrial receptivity. It is recommended to include it in pre-treatment screening, especially for those over 35 or with a history of failed transfers.
• Thyroid Autoantibodies: Even if TSH is within the normal range (<4.2 mIU/L), positive TPOAb or TGAb increases the risk of miscarriage. Some Thai hospitals require TSH to be controlled below 2.5 mIU/L before starting a cycle, and those with positive antibodies need early intervention.
• Sperm DNA Fragmentation Index: A normal routine semen analysis does not guarantee normal DNA integrity. When DFI > 30%, embryo developmental potential decreases and miscarriage rate increases. DFI testing is highly valuable for men over 40, smokers, or those with varicocele.
• Blood Type and Irregular Antibody Screening: For Rh-negative blood type or presence of irregular antibodies, a blood preparation plan is needed in advance. Blood product management differs between Thailand and China; informing the hospital early can avoid passive waiting during the cycle.

V. Five Most Common Pitfalls

Based on patient feedback and clinical observations, the following five areas have the highest error rates and directly affect cycle progress.

1. Mutual Recognition of Test Results: Reports from some Chinese hospitals (e.g., chromosomal reports lacking karyotype images, infectious disease reports lacking quantitative values) may not be fully accepted by Thai hospitals. Solution: Send reports to the Thai hospital for pre-review before departure, or choose testing facilities in China with international reporting qualifications.
2. Inconsistent AMH Testing Timing: Although AMH can be tested at any time during the menstrual cycle, different laboratories use different methods (ELISA vs. chemiluminescence) with varying reference ranges. It is recommended to use the same laboratory for before-and-after comparisons to avoid misinterpretation due to methodological differences.
3. Improper Abstinence Period Before Semen Analysis: Abstinence that is too long (>7 days) or too short (<2 days) affects result accuracy. The optimal abstinence period is 2–5 days, and it should be consistent for repeat tests.
4. Chromosomal Testing Being Overlooked: Some patients think it is unnecessary if they are young or have no family genetic history. Clinically, about 0.5%–1% of infertile individuals have balanced chromosomal translocations or inversions. Without PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements), the risk of recurrent implantation failure and miscarriage is significantly increased.
5. Passport and Visa Validity Not Considered in Timeline: An IVF cycle in Thailand typically requires a stay of at least 28–35 days, and the passport must be valid for more than 6 months. The visa type (medical visa vs. tourist visa) affects the length of stay and ease of extension. These non-medical factors should be confirmed when initiating tests.

VI. Interpretation of Key Test Indicators

The following four indicators are the most relied upon for clinical decision-making during pre-treatment tests. Understanding their meaning helps patients and doctors set realistic expectations.

AMH (Anti-Müllerian Hormone)

• > 1.2 ng/mL: Normal ovarian reserve; expected oocyte yield is favorable.
• 0.5–1.2 ng/mL: Diminished reserve; stimulation protocol needs individualization, often using mild stimulation or gentle protocols.
• < 0.5 ng/mL: Severely diminished reserve; oocyte yield may be very low (1–3 eggs). Cycle feasibility should be assessed based on age and embryo quality.

Low AMH does not mean no chance, but expectations for oocyte yield should be realistic. Clinically, some patients with AMH 0.3 ng/mL still achieve transferable embryos, but the overall probability decreases with age.

FSH (Follicle-Stimulating Hormone)

• < 8 IU/L: Normal ovarian function.
• 8–12 IU/L: Mildly diminished ovarian reserve; response to stimulation may be suboptimal.
• > 12 IU/L: Indicates reduced ovarian function; clinically assessed together with AMH.

FSH is only meaningful when measured on cycle day 2–3. A single elevated FSH does not necessarily mean ovarian failure, but attention is needed if it is elevated for two consecutive cycles.

Antral Follicle Count (AFC)

• > 12: Suggests polycystic ovary tendency or good ovarian reserve.
• 5–12: Normal range.
• < 5: Diminished reserve, usually consistent with low AMH.

Sperm DNA Fragmentation Index (DFI)

• < 15%: Normal; minimal impact on embryo development.
• 15%–30%: Mildly elevated; should be assessed together with morphology and sperm count.
• > 30%: Significantly elevated; associated with lower fertilization rates, lower blastocyst formation rates, and higher miscarriage rates.

VII. Special Situations and Decision Pathways

Can I still do Thailand IVF with low AMH?

Yes. Low AMH mainly affects oocyte quantity, not directly embryo quality. For AMH ≤ 0.5 ng/mL, common clinical strategies include: ① Using mild stimulation or natural cycle protocols to reduce medication costs and cycle cancellation rates; ② Accumulating embryos through consecutive retrievals before transfer; ③ Combining growth hormone pretreatment to improve follicular development synchrony. The prerequisite is that the patient has realistic expectations about poor ovarian response and accepts that multiple cycles may be needed to obtain sufficient embryos.

What additional preparations are needed for advanced age IVF in Thailand?

Women over 40 should add the following during pre-treatment: ① Uterine cavity evaluation (3D ultrasound or hysteroscopy); ② Genetic counseling and discussion of PGT-A feasibility; ③ Basic health assessment including heart, blood pressure, blood sugar, etc., to rule out medical risks of advanced maternal age. Men should also complete sperm DNA fragmentation index testing, as the impact of declining sperm quality in older men on embryos is often underestimated.

History of recurrent implantation failure or miscarriage

In-depth investigation is needed: ① Uterine factors (chronic endometritis, adhesions, polyps); ② Immune factors (antiphospholipid antibodies, NK cell activity, etc., though immune screening is controversial and should be guided by a reproductive immunology specialist); ③ Embryo chromosomal aneuploidy (PGT-A); ④ Chromosomal karyotype of both partners (to rule out balanced translocations). Pre-treatment tests should be targeted based on these findings, rather than blindly adding tests.

Timeline Reminder

Pre-treatment tests for Thailand IVF are not a one-time task. Pay special attention to the following milestones:

• 3 months before traveling to Thailand: Complete chromosomal karyotyping, infectious disease screening, AMH, and male semen analysis. Also confirm passport validity (>6 months) and visa type.
• 1–2 months before traveling to Thailand: Complete hormone panel, AFC, and hysteroscopy (if needed). Submit all reports to the Thai hospital for pre-review.
• 2 weeks before traveling to Thailand: Ensure all report translations or notarized copies are ready. Finalize the cycle start date with the Thai hospital.

Test results are dynamic, especially AMH and semen parameters. If more than 6 months have passed since the initial tests, or if there has been major surgery, severe infection, or significant decline in ovarian function, retest relevant items before traveling to Thailand to avoid making decisions based on outdated data.

This content is compiled based on routine clinical practice in assisted reproduction. The specific examination plan should be based on the individualized assessment of the attending physician. Test items and validity periods may vary depending on the hospital, country, and individual circumstances.